Cargando…
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
Developing an intervention that results in virologic control following discontinuation of antiretroviral therapy (ART) is a major objective of HIV-1 cure research. In this study, we investigated the therapeutic efficacy of a vaccine consisting of adenovirus serotype 26 (Ad26) and modified vaccinia A...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117189/ https://www.ncbi.nlm.nih.gov/pubmed/35585080 http://dx.doi.org/10.1038/s41541-022-00477-x |
| _version_ | 1784710277970788352 |
|---|---|
| author | Ventura, John D. Nkolola, Joseph P. Chandrashekar, Abishek Borducchi, Erica N. Liu, Jinyan Mercado, Noe B. Hope, David L. Giffin, Victoria M. McMahan, Katherine Geleziunas, Romas Murry, Jeffrey P. Yang, Yunling Lewis, Mark G. Pau, Maria G. Wegmann, Frank Schuitemaker, Hanneke Fray, Emily J. Kumar, Mithra R. Siliciano, Janet D. Siliciano, Robert F. Robb, Merlin L. Michael, Nelson L. Barouch, Dan H. |
| author_facet | Ventura, John D. Nkolola, Joseph P. Chandrashekar, Abishek Borducchi, Erica N. Liu, Jinyan Mercado, Noe B. Hope, David L. Giffin, Victoria M. McMahan, Katherine Geleziunas, Romas Murry, Jeffrey P. Yang, Yunling Lewis, Mark G. Pau, Maria G. Wegmann, Frank Schuitemaker, Hanneke Fray, Emily J. Kumar, Mithra R. Siliciano, Janet D. Siliciano, Robert F. Robb, Merlin L. Michael, Nelson L. Barouch, Dan H. |
| author_sort | Ventura, John D. |
| collection | PubMed |
| description | Developing an intervention that results in virologic control following discontinuation of antiretroviral therapy (ART) is a major objective of HIV-1 cure research. In this study, we investigated the therapeutic efficacy of a vaccine consisting of adenovirus serotype 26 (Ad26) and modified vaccinia Ankara (MVA) with or without an SIV Envelope (Env) gp140 protein with alum adjuvant in combination with the TLR7 agonist vesatolimod (GS-9620) in 36 ART-suppressed, SIVmac251-infected rhesus macaques. Ad26/MVA therapeutic vaccination led to robust humoral and cellular immune responses, and the Env protein boost increased antibody responses. Following discontinuation of ART, virologic control was observed in 5/12 animals in each vaccine group, compared with 0/12 animals in the sham control group. These data demonstrate therapeutic efficacy of Ad26/MVA vaccination with vesatolimod but no clear additional benefit of adding an Env protein boost. SIV-specific cellular immune responses correlated with virologic control. Our findings show partial efficacy of therapeutic vaccination following ART discontinuation in SIV-infected rhesus macaques. |
| format | Online Article Text |
| id | pubmed-9117189 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91171892022-05-20 Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques Ventura, John D. Nkolola, Joseph P. Chandrashekar, Abishek Borducchi, Erica N. Liu, Jinyan Mercado, Noe B. Hope, David L. Giffin, Victoria M. McMahan, Katherine Geleziunas, Romas Murry, Jeffrey P. Yang, Yunling Lewis, Mark G. Pau, Maria G. Wegmann, Frank Schuitemaker, Hanneke Fray, Emily J. Kumar, Mithra R. Siliciano, Janet D. Siliciano, Robert F. Robb, Merlin L. Michael, Nelson L. Barouch, Dan H. NPJ Vaccines Article Developing an intervention that results in virologic control following discontinuation of antiretroviral therapy (ART) is a major objective of HIV-1 cure research. In this study, we investigated the therapeutic efficacy of a vaccine consisting of adenovirus serotype 26 (Ad26) and modified vaccinia Ankara (MVA) with or without an SIV Envelope (Env) gp140 protein with alum adjuvant in combination with the TLR7 agonist vesatolimod (GS-9620) in 36 ART-suppressed, SIVmac251-infected rhesus macaques. Ad26/MVA therapeutic vaccination led to robust humoral and cellular immune responses, and the Env protein boost increased antibody responses. Following discontinuation of ART, virologic control was observed in 5/12 animals in each vaccine group, compared with 0/12 animals in the sham control group. These data demonstrate therapeutic efficacy of Ad26/MVA vaccination with vesatolimod but no clear additional benefit of adding an Env protein boost. SIV-specific cellular immune responses correlated with virologic control. Our findings show partial efficacy of therapeutic vaccination following ART discontinuation in SIV-infected rhesus macaques. Nature Publishing Group UK 2022-05-18 /pmc/articles/PMC9117189/ /pubmed/35585080 http://dx.doi.org/10.1038/s41541-022-00477-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Ventura, John D. Nkolola, Joseph P. Chandrashekar, Abishek Borducchi, Erica N. Liu, Jinyan Mercado, Noe B. Hope, David L. Giffin, Victoria M. McMahan, Katherine Geleziunas, Romas Murry, Jeffrey P. Yang, Yunling Lewis, Mark G. Pau, Maria G. Wegmann, Frank Schuitemaker, Hanneke Fray, Emily J. Kumar, Mithra R. Siliciano, Janet D. Siliciano, Robert F. Robb, Merlin L. Michael, Nelson L. Barouch, Dan H. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques |
| title | Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques |
| title_full | Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques |
| title_fullStr | Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques |
| title_full_unstemmed | Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques |
| title_short | Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques |
| title_sort | therapeutic efficacy of an ad26/mva vaccine with siv gp140 protein and vesatolimod in art-suppressed rhesus macaques |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117189/ https://www.ncbi.nlm.nih.gov/pubmed/35585080 http://dx.doi.org/10.1038/s41541-022-00477-x |
| work_keys_str_mv | AT venturajohnd therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT nkololajosephp therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT chandrashekarabishek therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT borducchierican therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT liujinyan therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT mercadonoeb therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT hopedavidl therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT giffinvictoriam therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT mcmahankatherine therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT geleziunasromas therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT murryjeffreyp therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT yangyunling therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT lewismarkg therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT paumariag therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT wegmannfrank therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT schuitemakerhanneke therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT frayemilyj therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT kumarmithrar therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT silicianojanetd therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT silicianorobertf therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT robbmerlinl therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT michaelnelsonl therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques AT barouchdanh therapeuticefficacyofanad26mvavaccinewithsivgp140proteinandvesatolimodinartsuppressedrhesusmacaques |